Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 150


Interleukin-13 receptor α2 DNA prime boost vaccine induces tumor immunity in murine tumor models.

Nakashima H, Fujisawa T, Husain SR, Puri RK.

J Transl Med. 2010 Nov 10;8:116. doi: 10.1186/1479-5876-8-116.


Characterization of a novel human tumor antigen interleukin-13 receptor alpha2 chain.

Kawakami K, Terabe M, Kawakami M, Berzofsky JA, Puri RK.

Cancer Res. 2006 Apr 15;66(8):4434-42.


Highly persistent and effective prime/boost regimens against tuberculosis that use a multivalent modified vaccine virus Ankara-based tuberculosis vaccine with interleukin-15 as a molecular adjuvant.

Kolibab K, Yang A, Derrick SC, Waldmann TA, Perera LP, Morris SL.

Clin Vaccine Immunol. 2010 May;17(5):793-801. doi: 10.1128/CVI.00006-10. Epub 2010 Mar 31.


[Novel vaccines against M. tuberculosis].

Okada M.

Kekkaku. 2006 Dec;81(12):745-51. Review. Japanese.


Intratumoral therapy with IL13-PE38 results in effective CTL-mediated suppression of IL-13Ralpha2-expressing contralateral tumors.

Kawakami K, Terabe M, Kioi M, Berzofsky JA, Puri RK.

Clin Cancer Res. 2006 Aug 1;12(15):4678-86.


Epigenetic modulation enhances the therapeutic effect of anti-IL-13R(alpha)2 antibody in human mesothelioma xenografts.

Takenouchi M, Hirai S, Sakuragi N, Yagita H, Hamada H, Kato K.

Clin Cancer Res. 2011 May 1;17(9):2819-29. doi: 10.1158/1078-0432.CCR-10-2986. Epub 2011 Feb 28.


A novel combination immunotherapy for cancer by IL-13Rα2-targeted DNA vaccine and immunotoxin in murine tumor models.

Nakashima H, Terabe M, Berzofsky JA, Husain SR, Puri RK.

J Immunol. 2011 Nov 15;187(10):4935-46. doi: 10.4049/jimmunol.1102095. Epub 2011 Oct 17.


Interleukin 13 mediates signal transduction through interleukin 13 receptor alpha2 in pancreatic ductal adenocarcinoma: role of IL-13 Pseudomonas exotoxin in pancreatic cancer therapy.

Shimamura T, Fujisawa T, Husain SR, Joshi B, Puri RK.

Clin Cancer Res. 2010 Jan 15;16(2):577-86. doi: 10.1158/1078-0432.CCR-09-2015. Epub 2010 Jan 12.


Electroporation as a "prime/boost" strategy for naked DNA vaccination against a tumor antigen.

Buchan S, Grønevik E, Mathiesen I, King CA, Stevenson FK, Rice J.

J Immunol. 2005 May 15;174(10):6292-8.


IL-13 receptor-directed cancer vaccines and immunotherapy.

Nakashima H, Husain SR, Puri RK.

Immunotherapy. 2012 Apr;4(4):443-51. doi: 10.2217/imt.12.28. Review.


Identification of interleukin-13 receptor alpha2 peptide analogues capable of inducing improved antiglioma CTL responses.

Eguchi J, Hatano M, Nishimura F, Zhu X, Dusak JE, Sato H, Pollack IF, Storkus WJ, Okada H.

Cancer Res. 2006 Jun 1;66(11):5883-91.


Vaccine therapy of established tumors in the absence of autoimmunity.

Hodge JW, Grosenbach DW, Aarts WM, Poole DJ, Schlom J.

Clin Cancer Res. 2003 May;9(5):1837-49.


DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model.

Zhang H, Wang Y, Liu C, Zhang L, Xia Q, Zhang Y, Wu J, Jiang C, Chen Y, Wu Y, Zha X, Yu X, Kong W.

Cancer Immunol Immunother. 2012 Oct;61(10):1857-67. Epub 2012 Jun 17.


Perforin and gamma interferon expression are required for CD4+ and CD8+ T-cell-dependent protective immunity against a human parasite, Trypanosoma cruzi, elicited by heterologous plasmid DNA prime-recombinant adenovirus 5 boost vaccination.

de Alencar BC, Persechini PM, Haolla FA, de Oliveira G, Silverio JC, Lannes-Vieira J, Machado AV, Gazzinelli RT, Bruna-Romero O, Rodrigues MM.

Infect Immun. 2009 Oct;77(10):4383-95. doi: 10.1128/IAI.01459-08. Epub 2009 Aug 3.


Early Treg suppression by a listeriolysin-O-expressing E. coli vaccine in heterologous prime-boost vaccination against cancer.

Dai MS, Vassaux G, Xu M, You RI, Hsieh YF, Ouisse LH, Lo KY, Sytwu HK, Chao TY.

Vaccine. 2012 Nov 6;30(48):6903-11. doi: 10.1016/j.vaccine.2012.09.001. Epub 2012 Sep 14.


Improved efficacy of DNA vaccination against prostate carcinoma by boosting with recombinant protein vaccine and by introduction of a novel adjuvant epitope.

Lu Y, Ouyang K, Fang J, Zhang H, Wu G, Ma Y, Zhang Y, Hu X, Jin L, Cao R, Fan H, Li T, Liu J.

Vaccine. 2009 Aug 27;27(39):5411-8. doi: 10.1016/j.vaccine.2009.06.089. Epub 2009 Jul 17.


Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.

Cancer Res. 2001 Aug 15;61(16):6178-84.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk